Top Markets
#1 Akedo Akedo +54.06%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +50.26%
#4 Cross Cross +47.18%
#5 Black Phoenix Black Phoenix +34.15%
#6 Velvet Velvet +31.77%
#7 OVERTAKE OVERTAKE +18.70%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.05%
#9 Movement Movement +13.43%
#10 Perle Perle +11.98%
Coin of the day
Akedo Akedo
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Aceragen, Inc. Aceragen, Inc.

Aceragen, Inc.

ACGN
Kedudukan dalam Saham #39037
Aceragen, Inc., a biopharmaceutical firm in its clinical development phase,... Aceragen, Inc., a biopharmaceutical firm in its clinical development phase, operates out of Exton, Pennsylvania, and was founded in 1989. The company, which transitioned from Idera Pharmaceuticals, Inc. and adopted its current name in January 2023, concentrates on the discovery, advancement, and bringing to market of therapeutic agents for uncommon lung and autoimmune conditions exclusively within the United States. Its product development pipeline includes ACG-701, currently undergoing Phase 2 clinical evaluation for both cystic fibrosis pulmonary exacerbations and melioidosis, as well as ACG-801, which is being developed to address Farber disease. Moreover, Aceragen maintains a partnership and option agreement with Scriptr Global, Inc. This collaboration aims to pinpoint, research, and cultivate gene therapy options intended for the management, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia.
Harga Saham
$0.38
Disegerakkan terakhir: 2023-09-01
Modal Pasaran
$677.16K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Aceragen, Inc. (ACGN)

Kategori

Healthcare
Pendapatan untuk Aceragen, Inc. (ACGN)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Aceragen, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Aceragen, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE